Company: PGEN
Filing Date: 2025-05-14
Form Type: 10-Q
Source: 0001356090-25-000019
Chunk: 14

Company: PRECIGEN, INC.
Filing Date: 2025-05-14
Form: 10-Q
Item: Part I, Item 1
Chunk 14
---
 preference of $80,580 as of March 31, 2025.29,518 28,218 Shareholders' equity (deficit)Common stock, no par value, 400,000,000 shares authorized as of March 31, 2025 and December 31, 2024; 295,135,060 shares and 292,869,097 shares issued and outstanding as of March 31, 2025 and December 31, 2024, respectively.— — Additional paid-in capital2,130,787 2,129,207 Accumulated deficit(2,144,859)(2,090,706)Accumulated other comprehensive income12 12 Total shareholders' (deficit) equity (14,060)38,513 Total liabilities, mezzanine equity and shareholders' (deficit) equity$128,787 $145,266 

The accompanying notes are an integral part of these condensed consolidated financial statements.

5

Table of Contents

Precigen, Inc. and Subsidiaries

Condensed Consolidated Statements of Operations

(Unaudited)

(Amounts in thousands, except share and per share data)Three Months Ended  March 31,20252024RevenuesProduct revenues$203 $138 Service revenues1,115 919 Other revenues23 8 Total revenues1,341 1,065 Operating ExpensesCost of products and services1,100 1,075 Research and development10,478 14,249 Selling, general and administrative12,359 10,151 Total operating expenses23,937 25,475 Operating loss(22,596)(24,410)Other Income (Expense), NetChange in fair value of warrant liabilities(32,481)— Interest expense(1)(2)Interest income918 608 Other income, net7 37 Total other (expense) income, net(31,557)643 Loss before income taxes(54,153)(23,767)Income tax benefit— 29 Net loss$(54,153)$(23,738)Net loss per shareNet loss per share, basic and diluted$(0.18)$(0.10)Weighted average shares outstanding, basic and diluted293,879,653 249,220,335 

The accompanying notes are an integral part of these condensed consolidated financial statements.

6

Precigen, Inc. and Subsidi